Biocentury Emerging Company Profile - Accession: precisely targeted oncolytic viruses

davidtokley
Nov 29, 2022
1 min read

Updated: Jan 3, 2023

Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism - read the article by Richard Guy, Biopharma Analyst, here >

Recent Posts

See All

Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK

Accession Therapeutics submits CTA to the UK MHRA to start Phase 1 first-in-human clinical trial with lead TROCEPT anti-cancer immunotherapy

Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate

Comments